Økonomisk støtte
Den økonomiske kjernestøtten til Broegelmann Research Laboratory kommer fra Broegelmann Foundation, med fondet administrert av The Broegelmann Research Board.
Fra venstre: Styreleder, advokatfullmektig Bernt Jacob Pettersen, professor Robert Bjerknes MD, ph.d., overlege ved BRL Kate Froland (ikke styremedlem), professor Lars A. Akslen.
Foto/ill.:
Helena Harris
Hovedinnhold
Andre nåværende store tilskudd er oppført nedenfor
- 2019 – 2024 Piotr Mydel: National Institutes of Health (RO1 DE022597)“Bacterial peptidylarginine deiminase, a link between gums and joint disease”, Total 6.4 mill NOK
- 2020-2023 Foundation for Research in Rheumatology (FOREUM) “Genetic variants associated with Sjögren’s syndrome leading to differential gene expression in males and females and their functional impact on the immune system”; Karolinska Institutet v/Marie Wahren Herlenius er coordinator, UiB og Harvard er partnere. Appel/Jonsson Total 1 500 000 NOK
- 2020 – 2023 Piotr Mydel: National Science Center Poland (2019/33/B/NZ4/01889) “Protein Carbamylation in Hemostatic Dysfunctions in Chronic Kidney Disease”; Total 505 000 €
- 2020 – 2023 Piotr Mydel: EU Joint Programme – Neurodegenerative Disease Research (EC/JPND; ES655895) “Alzheimer’s disease as a comorbidity of chronic periodontitis with Porphyromonas gingivalis as a causative link between both diseases” Total 575 000 €
- 2021 – 2024 Piotr Mydel: EC/Grieg “Novel mechanisms of PAD activity regulation. Substrate specificity and and activation of peptidyl arginine deiminases in the context of RA” Total 499 000 €
- 2019-2024 Roland Jonsson: The European Commission Horizon 2020 contract NECESSITY (IMI2-JU/EU/H2020 nr. 806975) “New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients”
- 2021-2025 Yenan Bryceson: Norwegian Research Council ‘’Engineering NK cells for improved functonality in immunotherapy’’ Total 12 mill NOK
- 2021-2025 Marie Wahren Herlenius: Norwegian Research Council ‘’The molecular basis of sex differences in Sjögren’s syndrome’’ Total 10 mill NOK
Vi takker bidragsyterne for deres økonomiske støtte!
08.05.2024